Monoclonal antibodies to anthrax protective antigen
US9512205B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Inventors
Key dates
| Filing date | May 2, 2014 |
| Grant date | Dec 6, 2016 |
| Priority date | — |
| Expiry date | May 14, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a Bacillus anthracis infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against Bacillus anthracis infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.